RecruitingNCT06725693
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
Sponsor
Tianjin Medical University
Enrollment
500 participants
Start Date
Feb 1, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria1
- \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria1
- \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Interventions
DIAGNOSTIC_TEST18F/68Ga-Exendin 4
Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06725693
Related Trials
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
NCT074641321 location
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT0407530518 locations
Development of New Diagnostic Tools in Capsule Endoscopy
NCT061522891 location
Diagnosing and Treating Low Blood Sugar Levels
NCT000012761 location
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
NCT049830957 locations